查找临床试验
已按「前列腺癌」检索，对应国际通用词 prostate cancer
共找到 12 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 11:24，每 5 分钟自动同步Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients
Taiwan
年龄 30 Years – 100 Years
National Taiwan University Hospital
A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients
China
年龄 40 Years – 75 Years
Shanghai Jiao Tong University School of Medicine
The Investigation of New Biological Markers for Prostate Cancer Diagnosis and Management in Chinese Population
Hong Kong
年龄 18 Years – 不限
Chinese University of Hong Kong
Plasma Exosomal RNA Signature for Prostate Cancer Bone Metastasis
China
年龄 18 Years – 不限
Xijing Hospital
A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.
China
年龄 18 Years – 不限
Bayer
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
United States、China、United Kingdom
年龄 18 Years – 不限
BioNTech SE
Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer
China
年龄 18 Years – 75 Years
The Affiliated Hospital of Xuzhou Medical University
Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
China
年龄 18 Years – 不限
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
United States、China、France、Germany、Italy 等 12 国
年龄 18 Years – 不限
Astellas Pharma Global Development, Inc.
A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
China
年龄 18 Years – 75 Years
Hangzhou DAC Biotechnology Co., Ltd.
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
United States、China
年龄 18 Years – 不限
Phrontline Biopharma
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
United States、Australia、Canada、Chile、Colombia 等 12 国
年龄 18 Years – 不限
Merck Sharp & Dohme LLC